Multi-modular Chimeric Antigen Receptor T Cells tarGeting B7-H3 in Children, Teenage & Young Adult Sarcoma

MIGHTY is a multicentre, open label, phase 1 clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children, teenagers and young adults aged 1-24 with relapsed or refractory (r/r) rhabdomyosarcoma (RMS), Ewing sarcoma (ES) or desmoplastic small round cell tumour (DSRCT). The study will assess the feasibility of generating the ATIMP and administering hBRCA84D CAR T cells to patients with r/r RMS, ES or DSRCT.

Trial Details

NCT ID
NCT07751380
Phase
PHASE1
Sponsor
University College, London
Status
RECRUITING
Cancer Type
Rhabdomyosarcoma Sarcoma
Interventions
  • Biological/Vaccine: hBRCA84D CAR T cells
Locations (sample)
  • London, United Kingdom|51.50853,-0.12574
  • London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Age ≥ 1 and ≤ 24 years.
  • Tissue diagnosis of RMS, ES or DSRCT
  • Expression of B7-H3 in the tumour
  • Relapsed or refractory disease after one or multiple lines of previous treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Rhabdomyosarcoma Sarcoma Trials on Trialify →